Long-term survival in patients with HER2-positive metastatic breast cancer treated with trastuzumab as first-line therapy: Seven-year follow-up of the French Observational Hermine Study.

Metastatic Breast ◽

First Line ◽

Her2 Positive ◽

Term Survival ◽

First Line Therapy ◽

Long term survival of vinorelbine (N) and trastuzumab (H) as first line therapy for HER2-positive metastatic breast cancer patients (HER2+MBC) (pts)

Journal of Clinical Oncology ◽

10.1200/jco.2005.23.16_suppl.587 ◽

2005 ◽

Vol 23 (16_suppl) ◽

pp. 587-587 ◽

Cited By ~ 2

Author(s):

A. Chan ◽

L. Petruzelka ◽

M. Untch ◽

M. Martin ◽

M. Gil Gil ◽

...

Keyword(s):

Breast Cancer ◽

Metastatic Breast ◽

Breast Cancer Patients ◽

First Line ◽

Her2 Positive ◽

Term Survival ◽

First Line Therapy ◽

Final results from PERUSE, a global study of pertuzumab (P), trastuzumab (H) and investigator’s chosen taxane as first-line therapy for HER2-positive locally recurrent/metastatic breast cancer (LR/mBC)

10.1055/s-0041-1730221 ◽

2021 ◽

Author(s):

A Schneeweiss ◽

D Miles ◽

E Ciruelos ◽

F Puglisi ◽

T Peretz-Yablonski ◽

...

Keyword(s):

Breast Cancer ◽

Metastatic Breast ◽

First Line ◽

Her2 Positive ◽

First Line Therapy ◽

Line Therapy ◽

Global Study ◽

Locally Recurrent

Abstract P6-17-14: Eribulin, trastuzumab, and pertuzumab as first-line therapy for patients with HER2-positive metastatic breast cancer: A multicenter, collaborative, open-label, phase II clinical trial for the SBCCSG-36 investigators

10.1158/1538-7445.sabcs18-p6-17-14 ◽

2019 ◽

Author(s):

K Inoue ◽

J Ninomiya ◽

K Okubo ◽

T Nakakuma ◽

H Yamada ◽

...

Keyword(s):

Breast Cancer ◽

Clinical Trial ◽

Metastatic Breast ◽

First Line ◽

Her2 Positive ◽

Open Label ◽

First Line Therapy ◽

Line Therapy ◽

Open Label Phase

Trastuzumab combined with doublet or single-agent chemotherapy as first-line therapy for HER2-positive metastatic breast cancer

Breast Cancer Research and Treatment ◽

10.1007/s10549-017-4592-y ◽

2017 ◽

Vol 168 (2) ◽

pp. 337-348 ◽

Cited By ~ 2

Author(s):

Y. F. Yu ◽

Y. Wang ◽

T. P. Fu ◽

K. Chen ◽

J. Q. Liu ◽

...

Keyword(s):

Breast Cancer ◽

Single Agent ◽

Metastatic Breast ◽

First Line ◽

Her2 Positive ◽

First Line Therapy ◽

Line Therapy ◽

Single Agent Chemotherapy

Evaluation of vinorelbine (N) and trastuzumab (H) as first-line therapy for patients (pts) with HER2- positive metastatic breast cancer (HER2+ MBC): Impact on clinical response and cardiac function

Journal of Clinical Oncology ◽

10.1200/jco.2004.22.90140.636 ◽

2004 ◽

Vol 22 (14_suppl) ◽

pp. 636-636

Author(s):

V. Guillem Porta ◽

M. Martin ◽

M. Gil Gil ◽

P. Kellokumpu-Lehtinen ◽

F. Majois ◽

...

Keyword(s):

Breast Cancer ◽

Cardiac Function ◽

Clinical Response ◽

Metastatic Breast ◽

First Line ◽

Her2 Positive ◽

First Line Therapy ◽

A multinational phase II study of Navelbine (N) and Herceptin (H) as first-line therapy for patients with HER2-positive metastatic breast cancer (HER2+ MBC)

European Journal of Cancer Supplements ◽

10.1016/s1359-6349(04)90846-4 ◽

2004 ◽

Vol 2 (3) ◽

pp. 127 ◽

Cited By ~ 1

Author(s):

M Untch ◽

S Kahlert ◽

L Petruzelka ◽

M Martin ◽

V Guillem-Porta ◽

...

Keyword(s):

Breast Cancer ◽

Phase Ii ◽

Phase Ii Study ◽

Metastatic Breast ◽

First Line ◽

Her2 Positive ◽

First Line Therapy ◽

Retrospective review of Her2 positive metastatic breast cancer patients who received Pertuzumab and Herceptin as a first line therapy at KFSH&RC (single institute experience) from 2013 to 2016

The Breast ◽

10.1016/s0960-9776(19)30245-0 ◽

2019 ◽

Vol 44 ◽

pp. S64

Author(s):

K. Suleman ◽

A. Mushtaq ◽

E. Haque ◽

A. Badran ◽

D. Ajarim ◽

...

Keyword(s):

Breast Cancer ◽

Cancer Patients ◽

Retrospective Review ◽

Metastatic Breast ◽

Breast Cancer Patients ◽

First Line ◽

Her2 Positive ◽

First Line Therapy ◽

Faculty Opinions recommendation of AVEREL: a randomized phase III Trial evaluating bevacizumab in combination with docetaxel and trastuzumab as first-line therapy for HER2-positive locally recurrent/metastatic breast cancer.

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature ◽

10.3410/f.717998592.793477025 ◽

2013 ◽

Author(s):

Ana Maria Gonzalez-Angulo

Keyword(s):

Breast Cancer ◽

Metastatic Breast ◽

Phase Iii ◽

First Line ◽

Her2 Positive ◽

Phase Iii Trial ◽

First Line Therapy ◽

Line Therapy ◽

Locally Recurrent

Abstract P5-21-14: Long-term survival in HER2-positive metastatic breast cancer treated with first-line trastuzumab: Real-life results from the Curie ESME database

10.1158/1538-7445.sabcs17-p5-21-14 ◽

2018 ◽

Author(s):

E Kaczmarek ◽

C Saint-Martin ◽

J-Y Pierga ◽

E Brain ◽

R Rouzier ◽

...

Keyword(s):

Breast Cancer ◽

Real Life ◽

Metastatic Breast ◽

First Line ◽

Her2 Positive ◽

Term Survival ◽

Long Term Survival

2108 POSTER Cardiac safety of trastuzumab in combination with epirubicin/ cyclophosphamide as first-line therapy in patients with HER2-positive metastatic breast cancer

European Journal of Cancer Supplements ◽

10.1016/s1359-6349(07)70870-4 ◽

2007 ◽

Vol 5 (4) ◽

pp. 216 ◽

Cited By ~ 2

Author(s):

M. Untch ◽

S. Tjulandin ◽

W. Jonat ◽

H. Meerpohl ◽

M. Lichinitser ◽

...

Keyword(s):

Breast Cancer ◽

Metastatic Breast ◽

Cardiac Safety ◽

First Line ◽

Her2 Positive ◽

First Line Therapy ◽